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Abstract
Background: The cohort was commenced to examine women’s health from midlife (45–55 years) before the
menopausal transition and into ageing.
Methods: Randomised selection and assessment of 2,001 women living in the Melbourne metropolitan area was
conducted by the Roy Morgan Centre in 1990/91. Of the 779 women who met the entry criteria for the longitudinal
follow-up (aged 45–55 years, menstruating, having a uterus and at least one ovary and not taking hormone therapy)
438 agreed to be seen annually across the menopausal transition from 1992 to 1999. Longitudinal prospective follow-up
since 2000 has continued intermittently (2002/03, 2004/05, 2012/13, 2014/15). Data collection has included fasting
biomarkers in each year since 1992, clinical assessment, lifestyle and quality of life data, physical measures and validated
questionnaire data. Participants have consented to data linkage and, to date, mammogram and BioGrid data have been
accessed. Biobank storage including serum, deoxyribonucleic acid (DNA) storage and PAXgene tubes are maintained.
Discussion: The WHAP has contributed to over 200 published research findings, several books, and book chapters in a
variety of areas, including: health and wellbeing; mental and cognitive health; bone health; lifestyle, vascular risk and
prevention; women’s health and hormonal transition; and cross-cultural research.
With all participants now aged over 70 years, the cohort is ideally placed to answer key questions of healthy ageing in
women. With more than 25 years of longitudinal prospective follow-up this Australian dataset is unique in its duration,
breadth and detail of measures including clinical review and specialized disease-specific testing and biomarkers. Ongoing
follow-up into older ages for this long-running cohort will enable the association between mid to late-life factors and
healthy ageing to be determined. This is particularly valuable for the examination of chronic diseases which have a 20–30
year prodrome and to provide knowledge on multiple morbidities. The dataset has a unique opportunity
to improve our understanding of temporal relationships and the interactions between risk factors and comorbidities.
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Background
The Women’s Healthy Ageing Project (WHAP) was
initiated in 1990 to examine women’s health from
midlife, before the menopausal transition, into ageing.
The study is in a unique position to consider the life-
course temporal changes in risk and the development
of diseases of ageing, which due to the difficulty of
maintaining longitudinal cohorts is an under-developed
area of research. The driving vision of the scientific
management advisory board and study leaders has been
to use strategies outlined by the United States Centers
for Disease Control and Prevention: 1) epidemiology to
inform programs; 2) environmental approaches that
promote health and support healthy behaviours; and 3)
community resources linked to clinical services that
sustain improvements in management [1].
The WHAP is unique in Australia as existing cohort
studies from midlife (Australian Longitudinal Study of
Women’s Health (ALSWH) [2], Melbourne Collabora-
tive Cohort Study (MCCS), Household Incomes and Dy-
namics in Australia (HILDA)) do not have longitudinal
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assessments with physical measures, neuropsychological
evaluation, lifestyle, and biomarker measures. Those with
neuropsychiatric measures and biomarkers (Memory and
Ageing Study (MAS) [3], Australian Longitudinal Study of
Ageing (ALSA) [4], Australian Imaging, Biomarker and
Lifestyle Study (AIBL) [5]) have only obtained information
from those over 60 or 70 and the Path Through Life Study
(PATH) [6] has no published information on neuro-
psychological function available before 60. Australian
studies of ageing, like the Melbourne Longitudinal
Studies of Healthy Ageing (MELSHA) [7] have only
recruited after age 60. Few studies have detailed
follow-up and biomarker measures and the only other
study with amyloid imaging, AIBL, excluded individuals
with vascular pathology, precluding the potential to
understand this very influential factor contributing to
morbidity in ageing [8].
As the large gains in health demonstrated in men from
the 1960s to today are not matched in women [9], it is
important to support women’s epidemiological research.
Ninety percent of the gains in life expectancy for women
are spent with a disability [10, 11], with women more
likely to have a chronic illness, multiple disabilities [12],
and higher health service use [13]. In addition there is an
opportunity to address the significant lack of awareness of
modifiable risk in women [14] and the absence of women-
specific guidelines for risk modification, with most derived
from studies in male-only cohorts [15]. The WHAP is
committed to improving our understanding of risk factors
and the accrual of disease over time, and moving towards
improving overall health and wellbeing.
Methods
Study overview
The WHAP began in 1990, initially called the Mel-
bourne Women’s Midlife Health Project (MWMHP).
The study is unique in Australia and is a leader world-
wide in being able to draw on an accumulated database
incorporating biological, physical, and psychosocial mea-
sures of women’s experience from before the meno-
pausal transition into subsequent decades [16].
The study has extensive validated measures of midlife
health, lifestyle and biomarkers, including specialised
measures of hormones and hormone exposures [17]. The
outcome variables utilised in the study cover six major
streams of research: Quality of Life and Ageing, Mental
and Cognitive Health, Cardio - Vascular Health, Musculo-
skeletal and Bone Health, Lifestyle, and Women’s Health
and Hormonal Transitions. The research governance
structure of the WHAP includes oversight by a Scientific
Advisory Board comprised of leading clinicians and aca-
demic researchers who cover a variety of specialty areas,
as well as consumer representation [16].
The WHAP has demonstrated a successful model of
longitudinal prospective research for more than two
decades, attracting millions of dollars of philanthropic
and peer-reviewed grant funding in addition to industry
partnerships. It has published more than 200 peer-
reviewed publications, review articles and books in
women’s health, as well as contributing to websites,
media and educational series on women’s health. The
WHAP has formed international collaborations and held
an important role in the development of international
and national guidelines on women’s health.
Sample selection and recruitment
To be eligible for the original study, participants had to
be females aged between 45 and 55 years, and born in
Australia [18]. Participants were recruited through the
Roy Morgan Centre using randomly selected telephone
numbers from a computerised database of the metropol-
itan Melbourne “White Pages” telephone directory.
There were 54,078 calls made to households, with 9,329
of these calls (17.3 %) unanswered. Of the 44,749 calls
placed to households, 40,364 (90.2 %) were terminated
due to the household not having a woman available to
complete the interview or the woman did not meet eligi-
bility criteria (Australian-born women aged 45 to
55 years), and 1,447 (3.2 %) calls were terminated by the
household before study eligibility was established. There
were 2,938 (6.6 %) households called with a woman
eligible to complete the interview; 105 (3.6 %) of the
eligible women were unavailable due to being ill or
absent during the study period. Of those available for
the study (n = 2,833), 2,001 (70.6 %) women consented
to take part in the baseline 2 hour telephone question-
naire, with 832 (29.4 %) women not agreeing to partici-
pate. Ethics approval for the original study was granted
by the University of Melbourne Human Research Ethics
Committee (Approval number: 585008_A_O_89_0489).
In 1992, the 779 eligible participants from the baseline
phase of the study were invited to enroll in the follow-
up phase of the study involving annual longitudinal
follow-up. The inclusion criteria for this longitudinal
study were women from the baseline study for whom
menopausal status was able to be determined (had
menses in the previous 3 months, had an intact uterus
with at least one ovary, and were not taking oral contra-
ceptives or hormone therapy). Figure 1 shows the ac-
quisition for the original follow-up study. Of eligible
participants a total of 438 (56.2 %) agreed to participate.
An analysis of the characteristics of the women who
agreed to participate in the follow-up study and those
who did not showed that a greater proportion of those
in the study reported that they had more than 12 years
of education (34.3 vs. 24.3 %, p < .005), were in paid
employment (71.4 vs. 63.0 %, p < .05), had perceived
Szoeke et al. Women's Midlife Health  (2016) 2:5 Page 2 of 18
better health than most in comparison with women of
the same age (48.5 vs. 38.1 %, p < .005), had exercised at
least once a week (68.0 vs. 58.1 %, p < .005), had a
Papanicolaou smear in the last year (58.3 vs. 50.0 %, p < .05),
and had undergone dilatation and curettage (D&C; 46.5 vs.
38.4 %, ρ < .05) [19]. In contrast, women in both groups
were similar in the following measures: age, body mass
index (BMI), marital status, parity, symptoms, well-being,
interpersonal stress, number of surgical procedures, propor-
tion of current smokers, recent alcohol consumption,
household composition, proportion who had breast checks
in the last year, proportion who had a tubal ligation,
use of medications, treatment for chronic conditions,
and suffering from premenstrual complaints [19]. Re-
tention of the original cohort across the initial follow-
up period (1992 to 1999) was an impressive 88 %
[17], by 10 years follow-up retention was 74 %, with
more than 50 % follow-up in the 20th year [20] as
shown in Figs. 2 and 3. Ethics approval for the
WHAP longitudinal study was granted by the
University of Melbourne Human Research Ethics
Committee (approval numbers: 931149X (92–99), 010528
and 010411 (02–09), 1034765 and 1339373 (since 2012)).
Those retained in the study were more likely to have higher
levels of education and better health than those who were
lost to follow - up over the course of the study [21].
Procedure
The longitudinal follow-up of the WHAP were completed
annually for the first eight follow-ups and intermittently
Fig. 1 PRISMA Chart outlining the selection of the participants for the Women’s Healthy Ageing Project (WHAP) longitudinal study
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thereafter (see Fig. 3), with all follow-ups completed in
person. Participants were contacted by a researcher at
each time-point to confirm their continuation with the
study and to book a follow-up assessment time. Upon
booking the assessment, participants were mailed the
study information, participant consent form, and self-
administered questionnaires before their assessment.
Participants were asked to fast overnight (minimum
10 hours) prior to their appointment. Upon arrival for
assessment written informed consent was obtained and
blood samples were taken for biomarkers, genetic testing,
and biobank storage. Before the assessment commenced
participants were served breakfast. The duration for the
visit using the current protocol was approximately 4 hours
[20]. All participant data was stored under unique identifier
serial numbers and paper records of test results are kept




Information regarding the participant’s age and their
diagnosis of chronic medical conditions was obtained. Family
history of chronic medical conditions was also obtained and
a full list of medications recorded, in addition to any surgery
or admission to hospital. Participants were specifically asked
about 36 common diseases (including date of diagnosis and
treatment provided) and 33 common symptoms (including
severity scores). The Charlson Comorbidity Index [22] was
calculated, predicting participants’ 1 year mortality risk.
Sociological and demographics
These are addressed in the demographics questionnaire
and the core questionnaire. The questionnaires include
items such as participant age, marital status, education,
employment status, language, income, language, number of
pregnancies, number of births, and number of children.
Fig. 2 Cohort Longitudinal Follow-up and Retention
Fig. 3 Participants retention and measures at each time-point across 25 years of follow-up 1990–2015
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Quality of life
Items regarding social engagement, household compos-
ition, volunteer work, caring roles, and occupation were
included in the core questionnaires. A wellbeing score
was calculated from the Affectometer 2, a validated
assessment of negative and positive mood as well as psy-
chological wellbeing [23]. Self-reported health was mea-
sured using a brief questionnaire [24] at each follow-up.
From 2012 onwards both the Short-Form Health Survey
(SF-36) [25] (a 36-item health survey designed for use in
the general population which addresses both physical
and mental health) and the Activities of Daily Living
Inventory (ADLI) [26] were completed. The ADLI con-
sists of 23 items assessing changes in functional abilities
of the participant, as reported by an informant such as
the participant’s partner, child, or friend. The Short
Form of the Informant Questionnaire on Cognitive
Decline Evaluation (Short IQCODE) [27], included since
2012, also has items regarding participant function.
Fatigue was assessed in each year with the Piper Fatigue
Scale [28] included in 2014/15. Participants’ self-
perceptions and attitudes to women in the workplace
(1992, 1993), ageing [29] (1992, 1996), and menopause
[30] (1992, 1993, 1997, 1998, 1999, 2002) were also mea-
sured. The Life Satisfaction Index scale (LSI-A) [31] and
Life Satisfaction Index-Z scale (LSI-Z) [32] were admin-
istered in 1997. From 2004 onwards, questions regarding
grandparenting (if they had grandchildren and how
much time they spent minding their grandchildren) and
if their now adult children had been demanding of them
[33] were included.
Participants’ sexual functioning was assessed using the
Personal Experiences Questionnaire (PEQ) [34] from
1992 to 1999, with the Personal Experiences Question-
naire - Short Form (SPEQ) [35] used from 2002 onward.
The 12 items of the SPEQ were completed on a Likert
scale, and relate to sexual experiences, enjoyment and
thoughts, as well as the participant’s partner(s). The brief
version of the Female Sexual Distress Scale (FSDS) [36]
was used in 2002 and 2012 to measure participants’
personal distress related to sex and sexual functioning.
Consisting of 12 items, the scale differentiates between
women who are experiencing distress as a result of their
sexual experiences and those who are not.
Experience of violence and abuse
Participants’ experience of violence was assessed in 1997
using a modified version of the Conflicts Tactics Scale
(CTS) [37, 38]. The CTS asked participants about the
behaviours used by their husband/partner in resolving con-
flict or arguments, with the modification to the scale being
that participants were asked how frequently the 25 behav-
iours had occurred (never, once in the last year, more than
once in the last year, anytime other than the last year).
Participants were also asked about their experiences of both
physical violence and sexual abuse before and since the age
of 16 years. Participants completed the Vulnerability to
Abuse Screening Scale (VASS) [39] from 2012 onwards, a
12-item scale designed to screen women for elder abuse.
Lifestyle and prevention
Participants were asked about their alcohol consumption
(assessed as the number of standard drinks in the pre-
ceding 1 or 2 weeks) and smoking status (assessed as the
number of cigarettes per day smoked, with calculated
pack years) at each follow-up. Participants’ sleep was
assessed via questions regarding the number of days they
had trouble sleeping in the past 2 weeks and the severity
of any problems. Attendance at national screening ser-
vices (Papanicolaou smear, mammogram) was recorded,
as well as personal preventative measures such as breast
self-examinations. Mammography Imaging: The results
of all mammograms completed by BreastScreen Victoria,
a community breast screening programme, prior to 2002
were retrieved for consenting participants who did not
have a history of breast cancer (68 % of the 387 partici-
pants in 1999) [40]. Original right-craniocaudal mammo-
grams were examined; with the percent mammographic
density (PMD) calculated using the total breast area on the
mammogram and the area of dense tissue seen.
Physical activity and performance
Physical activity was recorded as the number of days in
the last 2 weeks participants engaged in any physical activ-
ity and in physical activity that made them short of breath.
In 1991 the types of physical activities that participants
engaged in was also recorded, with the total energy
expenditure per week calculated from this. Participants
were asked in 2004 to complete a squat and a 10 metre
jog. In 2012 the International Physical Activity Question-
naire (IPAQ) was added [41], which measures the number
of days in the last 2 weeks and the number of days a
month participants are engaged in physical activity for
recreation or leisure. Since 2012 several measures of
physical abilities were also included. The Timed Up and
Go test [42] measures the time taken to rise from a seated
position, walk 3 m from the chair, walk back to the chair
and sit down again. Hand Grip Strength [43] was
measured using a hand grip dynamometer. Participants
were asked to squeeze the dynamometer as hard as they
can, with the average result of three trials computed (in
kilograms (kg)). In 2016 participants are asked to walk
5 metre wearing their regular shoes and in their regular
pace, with the time taken to walk 4 metre recorded [44] as
walking the greater distance avoids slowing down before
reaching the 4 metre mark. Participants did not use a
walking aid for the test unless they were unable to walk
without using it.
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Nutrition and diet
Each year participants were asked about intake of alco-
hol in the last two weeks and if they had experienced
any loss of appetite, if they felt like not eating, or had
any weight changes. The Food Frequency Questionnaire
(FFQ) was used to assess participant nutrition in 1994,
with the Cancer Council Victoria Food Frequency Ques-
tionnaire (CCFFQ) [45] used in 1998, 2012/13, 2014/15.
The CCFFQ was developed specifically for use in
Australian adults and is self-administered. It lists 74 food
items grouped into four categories: cereal foods, sweets,
and snacks; dairy products, meats and fish; fruit; and
vegetables. A separate set of questions covers intake of
alcoholic beverages. Participants nominate how often
they consume the food items using a frequency response
option ranging from ‘Never’ to ‘3 or more times per
day’. It also includes three photographs of scaled portions
for four foods (used to calculate a portion size calibrator),
questions on the overall frequency of consumption of
fruits and vegetables (used to calibrate the overestimation
of these foods in the food list), and questions on con-
sumption of foods such as bread that do not fit easily into
the frequency format. Participants’ responses were used to
calculate their Dietary Inflammation Index (DII) [46].
Nutrient intake is derived from participants’ FFQ re-
sponses, which is in turn used to calculate their DII. The
DII predicts levels of inflammatory markers, and in turn,
health outcomes influenced by chronic inflammation.
Participants’ Mediterranean Diet Adherence score [47]
and Western Diet score was also calculated, as well as
their daily kilojoule, fat, protein, carbohydrate, sugars, and
starch intake, and levels of dietary vitamin B12, folate, cal-
cium, iron and other vitamins and minerals. Participants’
glycemic index and glycemic load were also calculated.
Menstruation and menopause
Participants were asked to report information regard-
ing their menstrual periods until time of final men-
strual period (FMP). In addition, questions specific to
their menstrual history before the age of 40 years
were included in 1994. Participants completed men-
strual diaries and were asked questions to establish
their menopausal status. Menopausal symptoms were
measured using the checklist devised by Kaufert and
Syrotuik [29, 48], with additional symptom items [49]
included from 1994 onward. Extensive structured
clinical interviews about hormone therapy (HT) use,
indications, formulations, compliance and satisfaction
were conducted.
Vascular health
Participants’ standing height (without shoes) was measured
to the nearest 0.1centimetre (cm), with the highest of two
measurements recorded. Weight was measured using
regularly calibrated scales. Participants were weighed whilst
wearing regular indoor clothing and no shoes, to the near-
est 0.1 kg. Head, waist (at narrowest part of the trunk) and
hip circumference were measured in cm. Triceps, biceps,
subscapular, and suprailiac skin fold measurements were
also taken from 1992 to 1999. Participants’ systolic blood
pressure (SBP) and diastolic blood pressure (DBP) was
measured utilizing a standardized blood pressure monitor.
In addition to the morbidity screening detailed above,
participants were asked about their experience of vascular
conditions, significant symptoms, and family history of
neurological, psychological, and vascular diseases and
events. Cardiovascular risk scores were calculated [50–52].
Body Composition Imaging: Dual-Energy X-ray Absorpti-
ometry (DEXA) scans were conducted at the Royal
Melbourne Hospital up to 3 times over the period of the
study (see Fig. 3). Both fat mass and lean tissue were mea-
sured as well as abdominal fat, with the measurement
region for abdominal fat defined as “the area between the
upper surface of the second lumbar vertebra, the lower
surface of the fourth lumbar vertebra, and the lateral
margins of the outer rib cage” [53].
Blood biomarkers
Following an overnight fast exceeding 10 hours, blood
samples (80 ml) were collected by peripheral venous
puncture into serum separator tubes. Within an hour of
blood collection, the tubes were centrifuged, with 27 ml
forwarded to a clinical pathology laboratory for immediate
analysis. In addition, separate whole and fractioned blood
samples from each participant were stored in liquid nitro-
gen in the biobank. The biobank consists of the remaining
blood, which was fractionated into the following compo-
nents: serum, plasma, platelets, red blood cell, white blood
cell (in dH20) and white blood cell (in RNAlater, Ambion).
These components were stored in liquid nitrogen in 92
aliquots (NUNC cryo-vials) which ranged in size from
0.25 ml to 1 ml. Stored blood samples were sourced from
three different tube types: lithium-heparin tubes, EDTA
tubes with added prostaglandin E1 (Sapphire Biosciences,
33.3 ng/ml), and serum tubes. Information on the assay
techniques used across the project is included in
Additional file 1. The blood biomarker analyses include:-
Hormonal assays Follicle Stimulating Hormone (FSH)
(international units (iu)/litre (l)), Estradiol (E) (picomole
(pmol)/l), immunoreactive inhibin (unit (u)/l), Luteinis-
ing Hormone (LH) (iu/l), Testosterone (T) (nanomole
(nmol)/l), Sex Hormone Binding Globulin (SHBG)
(nmol/l), Free Testosterone Index (FTI), Dehydroepian-
drosterone (DHEAS) (mmol/l), inhibinA (nanogram
(ng)/l), inhibinB (ng/l) measured by radioimmunoassay
and Thyroid Stimulating Hormone (TSH), Free Thyrox-
ine (FT4), Free Triiodothyronine (FT3).
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Lipid profile Total cholesterol (millimole (mmol)/l), tri-
glyceride (mmol/l), High Density Lipoprotein (HDL-C)
(mmol/l) and Low Density Lipoprotein (LDL-C) (mmol/l).
Glucose sensitivity Glucose, insulin (microunits (μunits)/
milliliter (ml)). Inflammatory markers: C-Reactive Pro-
tein (CRP) (milligram (mg)/l), homocysteine (mmol/l).
Vitamins: vitamin B12, vitamin D, serum folate, red
cell folate.
Electrolytes and renal function: sodium, potassium,
chloride, bicarbonate, anion gap, creatinine, Estimated
Glomerular Filtration Rate (eGFR), urea. Liver function
and proteins: Alanine Transaminase (AT), Alkaline Phos-
phatase (AP), Aspartate Transaminase (AST), Gamma
Glutamyl Transferase (GGT), bilirubin, Albumin (Alb),
Total Protein (TP). Metals: iron, ferritin, transferrin, ceru-
loplasmin, calcium, magnesium.
Full blood count, erythrocyte count, haematocrit,
haemoglobin, platelet count, red cell count, leucocyte
count, white cell differential, red cell differential, packed
cell volume, Erythrocyte Sediment Rate (ESR).
Genotyping Estrogen receptor polymoprhism, androgen
receptor polmorphism, cytochrome 17 polymorphism,
and apolipoprotein-E COMT, and Aromatase genotyping.
Musculoskeletal health
Participants were asked about their experiences of aches
and joint pains, back pain, diagnosed arthritis or osteo-
porosis, and falls and fractures. Since 1999, a skeletal
chart to note joints affected by pain and those with
physician diagnosed arthritis has been utilized. Strength
and balance testing was conducted in 2004/05. Quadri-
ceps strength was measured using a seated force gauge
test [54]. Participants sat in a chair (hips and knees in
flexed position) with a force gauge attached to the base
of the chair at the rear legs and a padded strap attached
to one of the participant’s legs, slightly above their ankle.
Participants were asked to extend the leg at the knee
causing an isometric contraction of the quadriceps, with
the quadriceps strength recorded as the maximum force
exerted in kg. Balance was assessed using a variety of
clinically recognised methods. The Step Test [55] was
used to assess dynamic balance. Participants were asked
to remove their shoes and stand with their feet parallel
and 10 cm apart, with a 7 cm high block placed 5 cm in
front of the participant. The test measured the number
of times the participant could place their foot fully on
the block and return it to the starting position (one
cycle) during a 15 second (s) trial, with a trial completed
for both feet. The participant’s score was the mean
number of cycles completed from both trials. Static
balance was assessed using a modified version of The
Clinical Test of Sensory Interaction and Balance [56].
The test has four trials per leg, requiring the participant
to stand on one leg for a maximum of 30 s, with the
trials increasing in difficulty. For trial one, participants
were asked to stand unassisted on a firm surface on one
leg with their eyes open. This is repeated in trial two,
but with participants closing their eyes during the trial.
In trial three, participants were asked to stand unassisted
on a high-density foam surface on one leg with their
eyes open. In trial four, the participant repeats this with
their eyes closed during the trial.
Imaging bone mineral density Bone Mineral Density
(BMD) was measured using DEXA at the Bone Densio-
metry Unit at the Royal Melbourne Hospital, using a
Hologic QDR-1000 W densitometer in 1994, 1996 and
1998. Measures of BMD of the lumbar spine (the second
to the fourth lumbar vertebrae), femoral neck and the
proximal femur were taken. In addition to measures of
BMD, body composition including abdominal fat and
muscle mass were also obtained [57].
Hand and knee x-rays In 2002/03 x-rays of both knees
(antero-posterior view in full extension and skyline view
in 45° flexion) and both hands were conducted along
with C-telopeptide of type II collagen (CTX II) bio-
marker assays. The presence of osteophytes or joint
narrowing evident in the x-rays in comparison to a
published atlas of individual features [58] was used to
categorise osteoarthritic disease using a four-point scale.
Two trained investigators, who were blinded to any
other participant information, independently scored the
x-rays, with good intra- and inter-observer agreement
[59]. Joint assessments were completed using validated
measures. For hand x-rays, joints included in the classifi-
cation are the distal interphalageal, proximal interphala-
geal, and the first carpo-metacarpal joint of the thumb
[60]. For knee x-rays, the presence of osteophytes or
joint narrowing was examined in the tibio-femoral and
patella-femoral joints [61].
Mental health
Participants were asked to report their personal and
family history of psychiatric illness, and medical history
of depression, anxiety and other psychiatric illness. Each
year mood was evaluated by semi-structured interview
and the Affectometer 2, which provides a validated
assessment of negative and positive mood as well as
psychological wellbeing [23]. Depressive symptom mea-
sures were obtained from the Centre for Epidemiological
Studies Depression Scale (CES-D) [62], administered
since 2002. Individuals were required to rate their
experience of 20 items on a 4-point Likert scale ranging
from “rarely/none of the time” to “mostly/all the time”
over the past week. In older populations somatic
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symptomatology can affect depression scales,therefore
since 2012 we have included the Geriatric Depression
Scale (GDS-15) [63]. Anxiety levels were obtained from
the Hassles Questionnaire [64] which addresses everyday
demands that may cause frustration and irritation, with
the 86-item version used in 1992 and 1993, and the 23-
item version used since 1994. In each year stress caused
by demands, worry, illness and death was also recorded.
The Hospital Anxiety and Depression Scale (HADS)
[65], a 14-item assessment of anxiety and depression de-
signed for use in those with physical health problems,
has been included since 2012/13.
Cognitive health
The initial neuropsychological test of cognition, first
completed in the 1998 follow-up was the Consortium to
Establish a Registry for Alzheimer’s Disease (CERAD)
[66] a 10-item supraspan word list score sensitive to
early changes associated with dementia [67, 68]. From
2002 cognition was evaluated by a comprehensive
neuropsychological evaluation, including measures of
episodic memory, executive function, and speed of pro-
cessing, and from 2012 CogState, a computerised cogni-
tive testing scale [20], was introduced. The psychometric
battery comprised several well-validated psychometric
and neuropsychological tests and a computerized test of
cognition since 2012. It includes tasks sensitive to the
presence of mild cognitive impairment and cognitive
decline. A clinical review panel reviewed all available
medical, psychiatric, and neuropsychological information
to confirm the cognitive health of individuals, and the
panel was blinded to amyloid imaging results. Classifica-
tions were made consistent with current international
criteria [14, 15].
The National Adult Reading Test (NART) [69] and the
Wechsler Test of Adult Reading (WTAR) [70] were used
to provide an estimate of premorbid intelligence quo-
tient (IQ). The Mini-Mental State Exam (MMSE) [71] is
a commonly used cognitive impairment assessment,
indicating the participant’s level of orientation, attention,
memory, language and praxis. The California Verbal
Learning Task-II (CVLT-II) [72] and the CERAD Word
List Recall Task [73] were used as measures of memory
and learning. To evaluate working memory, the digit
span tasks from the Wechsler Adult Intelligence Scale-
III (WAIS-III) [74] were used. The Stroop interference
task [75, 76] and Trail Making Test A and B [77] were
used as measures of executive function. The Tower of
London task [76] was used in 2002 and 2004 as a meas-
ure of executive function. The Controlled Oral Word
Association Test (COWAT) [78] and the Boston
Naming Test (BNT) [79] were included in the battery to
evaluate language. The Digit Symbol task, a sub-scale of
the WAIS-III [74], was used since 2012/13 to assess
speed of processing. In 2002 and 2004, the letter-
number sequencing task from the WAIS-III [74] and the
Symbol Digits Modalities Test (SDMT) [80] were used
as speed of processing tasks. The Logical Memory
subtest (story A) of the Wechsler Memory Scale IV
(WMS-IV) [81] was used to assess auditory memory
from 2012, with the Faces task from the Wechsler
Memory Scale III (WMS-III) [82] and the East Boston
Memory Test [83] used in 2002 and 2004.
The spatial tasks in the battery were the Rey Complex
Figure Test (RCFT) [84] and the Clock-Drawing Test
(CDT) [76]. The Block Design Task and the Judgment of
Line Orientation [74], both from the WAIS-III, were
used as measures of visiospatial function prior to 2012.
The Category Fluency task [85] assesses verbal executive
function in participants. The computerised CogState
battery [86] uses playing cards to test aspects of cog-
nition. The Clinical Dementia Rating (CDR) [87] is a
widely used clinical staging instrument for dementia,
useful for globally staging the level of impairment based
on a semi-structured interview. A detailed description of
the neuropsychologic variables and the relationship
between the different tests has been published [20].
In addition to the neuropsychological assessment,
cognitive health was also evaluated using self-report and
informant questionnaires. At each follow-up (FU) from
2002 participants were asked how their memory com-
pared to others their age, and from 2012 were asked if
they had experienced any problems with their memory
in the previous seven days. From 2012, the Memory
Complaint Questionnaire (MAC-Q) [88], a brief self-
rating questionnaire regarding the participant’s current
abilities compared to past abilities on shopping lists was
also used. The Short IQCODE [27] is an assessment of
subjective cognitive decline in the participant which is
completed by an informant.
The Neuropsychiatric Inventory (NPI) [89] was used
only for participants who had Alzheimer’s Disease (AD),
and is administered to an informant. The CDR [87] was
used to rate the severity of dementia symptoms, by asses-
sing performance in personal care, home and hobbies,
memory, orientation, judgment and problem-solving, and
community affairs.
Cerebral imaging
A subset of 60 participants had 3 T magnetic resonance
imaging (MRI; structural MRI and functional imaging)
in 2002/03 and all participants of the WHAP were of-
fered neuroimaging with 3 T MRI (structural MRI and
functional imaging) plus Positron Emission Tomography
(PET) with F-18 Florbetaben, a radioligand which en-
ables quantification of AD pathology (β-amyloid) in vivo
[90] in the 2012/13 follow up with 125 of 252 partici-
pants consenting. Over 50 % of participants had both
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PET and MRI compared with 12.5 % imaged in ADNI
I [91] and 25 % imaged from the original AIBL cohort
[5, 92]. All MRIs were performed on a Siemens 3 T
Tim Trio Scanner. Five MRI sequences and functional
magnetic resonance imaging (fMRI) are acquired: 1)
T1 weighted Magnetization Prepared Rapid Gradient
Echo (MPRAGE) MRI; isotropic 1 millimeteres (mm)
voxel (Repetition time (TR) = 2300 milliseconds (ms),
Echo time (TE) = 2.98 ms, flip angle = 9°); 2) 3D Fluid
Attenuated Inversion Recovery (FLAIR), voxel dimen-
sion 0.90 × 0.97 × 0.97 mm (TR = 6000 ms,TE = 421 ms,
flip angle = 120°, Inversion Time (TI) = 2100 ms); 3)
Turbo Spin Echo T2W, 3 mm thickness, 0 mm gap, in
plane resolution of 0.9 × 0.9 mm (TR = 3000 ms,TE =
101 ms); 4) Diffusion Tensor Imaging (DTI): Field-Of-
View (FOV) 240, 55 slices, 2.5/0 thickness, TR 8600,
TE 120, resolution 2.5 mm × 2.5 mm, B values 0 and
3000, 30 directions and bandwidth 1408; and 5) Arter-
ial Spin Labelling (ASL): FOV 192, 14 slices, 6/1.5
thickness, TR 2500, TE 11, resolution 64, TI (1) = 700,
TI (2) = 1800, bandwidth 2232 and 101 measurements.
These sequences permit volumetric MRI analysis and
evaluation of cerebrovascular pathology such as cere-
bral infarction and hyperintense white matter lesions,
as well as the performance of atrophy-correction for
PET data. fMRI, non-task related acquisition, was used
for assessment of the default networks. Blood Oxygen-
ation Level Dependent (BOLD) signal was collected
continuously for 6 min. Participants were asked to
keep eyes open and fixed on a projected cross hair.
BOLD contrast, single-shot, T2*-weighted, gradient-
Echo Planar Imaging (EPI) data was acquired continu-
ously with an 8-channel birdcage radio frequency head
coil. Each scan generated 180 volumes of whole-brain,
41-slice acquisition (TR = 3000 ms, TE = 30 ms, flip
angle = 90°, voxel size = 3.0 mm3).
Resting state fMRI were conducted in 2002/03 and
2012/13 with T1-weighted images were acquired for
anatomic localization, and a gradient ECHO EPI se-
quence was employed for fMRI studies (flip angle of 60°,
TE 40 ms, 64by 64matrix, 24-cm FOV,TR = 1.5 s, 20
slices, slice thickness = 3.5 mm, skip = .5 mm). Event-
related fMRI was conducted in 2002/03 with a 10 s in-
terstimulus interval for activation tasks, with separate
verbal and figural recognition memory tests, similar to
the tasks used in previous PET studies [93, 94]. The
memory tests involved verbal and figural encoding of
abstract words and figures, yes/no recognition, and yes/
no matching, the latter of which was used as a control
task. In 2002/03 task oriented fMRI were acquired
through the cerebral hemispheres in an oblique axial
plane parallel to the anterior commissure - posterior
commissure (AC-PC) line.. Each of the memory tests
consisted of three separate tasks — encoding, yes/no
recognition, and yes/no matching (control). Task order
was: verbal encoding, figural encoding, 20-min delay
concurrent with structural image acquisition, verbal rec-
ognition, figural recognition, verbal matching and figural
matching. Test items were abstract words and figures. In
each of the two encoding tasks, participants viewed 20
targets individually and pressed the ‘yes’ button on a
hand-held unit each time an item appeared. In each of
the two recognition tasks, 40 items were shown indi-
vidually, and participants were instructed to discriminate
studied from unstudied items by responding ‘yes’ or ‘no’.
In each of the two matching tasks, 40 pairs of items
were shown, and participants were instructed to discrim-
inate identical from non-identical pairs.
F-18 florbetaben PET scans were conducted with par-
ticipants receiving 250 MBq of F-18 florbetaben intra-
venously, with a 20 min acquisition commencing 90 min
post injection. Standardized Uptake Values (SUV) were
calculated for all brain regions examined and SUV ratios
(SUVR) generated by normalising regional SUV using
the cerebellar cortex. Neocortical SUVR, a global meas-
ure of β-amyloid burden, is expressed as the average
SUVR of the area-weighted mean of frontal, superior
parietal, lateral temporal, lateral occipital and anterior
and posterior cingulate regions.
Results
Whilst studies across the menopausal transition are
prevalent in global research, there is very little informa-
tion about the natural history of cardiovascular, bone
and mental health functioning after the final menstrual
period and how these are affected by a range of factors
including premenopausal characteristics. This knowledge
may allow the early identification of women who are at
risk of disease, as well as clarifying the role of hormones
and identifying modifiable factors amenable via interven-
tions that could improve the health status of postmeno-
pausal women in the future. There is also scant knowledge
about changes in symptoms, mood, sexuality and other
aspects of quality of life in the post-menopause. The main




The first decade of the project focused on changes in
health and symptoms related to menopause [95]. The
association between hormonal changes and the meno-
pausal transition and the relationship of these changes
to symptoms [34, 49, 96] were an important contribu-
tion to women’s health. A novel aspect of the study was
the contribution not only to health outcomes [97], but
also self-rated health [24] and wellbeing [98–100]. The
WHAP study addressed the paucity of information on
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positive mood [18, 101], life satisfaction [102] and
attitudes to ageing [103] and their link to menopause
[104]. These novel aspects of the study and the avail-
ability of baseline measures in middle age will provide
important information on quality of life with ageing
moving forward.
Sexual function The study has led the research field in
women’s sexual functioning [105–115], in particular with
relevance to the changes over the menopause [116] and
the influence of ageing [117, 118]. Risk factors for sexual
dysfunction [119] have been identified and described for
the late postmenopause [120]. The extensive research in
this field has provided information on prevalence [121]
and highlighted important considerations for study
design [122] in measuring prevalence [123] and consid-
ering issues of reporting bias [124].
Violence in women The study reported on the influ-
ence of violence on women’s mental [125] and overall
health [126, 127]. It also reported the prevalence of
violence [128] in mid-aged women. In the latest follow-
ups we have included the VASS for a broader view of
violence in older people.
Mental and cognitive health
A unique aspect of the WHAP is the focus on positive,
not just negative, mood and the major factors which are
associated with a positive mood across early ageing have
been published [129]. The importance of lowered mood
across a woman’s life [23, 129–131] and relevance to
mental health treatments [132] and psychotropic drug
use [23, 129–131, 133] was also reported.
The WHAP cognitive database is unique in the world
with the availability of longitudinal prospective measures
from 45 years of age (including blood and imaging bio-
markers) combined with neuropsychiatric evaluations
from participants in their 50s and the availability of late-
life specialized neuro-imaging including fMRI and meas-
urement of cerebral amyloidosis [20]. Earliest changes in
cognitive decline from age 50 have been examined, and
the importance of social engagement [33, 134–137] and
minimizing vascular risk [138] to improve cognitive
health have been reported. These findings are important
in the context of the paucity of cognitive data in those
under 60 in conjunction with recent research noting that
the earliest changes of brain pathology associated with
dementia can already be found in 50 year olds [139]. In
addition the results of our early work have highlighted
the importance of longitudinal studies in cognitive re-
search as timing and duration of exposures is relevant to
outcomes for blood pressure [140], lipids [141], hor-
mones [142–146] and other modifiable risk factors
[142]. Genomic associations with early cognitive decline
have been examined with the influence of estrogen
polymorphism published [147]. There is an absence of
published normative data in Australia and the first
published normative papers came from the WHAP data
set for memory [148] and executive function [149].
Bone
Bone health in women is extremely important and the
first decade of the study BMD over the menopausal
transition [150], reported the bone loss in menopausal
women [151] and also identified key risk factors for
osteoporosis in Australian women [152]. There were
several studies that reported hormonal influence on
BMD [153, 154]. In our regular annual feedback, we
have had consistent requests from the participants to
have repeat BMD testing, and plans are currently under-
way to arrange this. This is not surprising given the high
incidence of osteoporosis in older women and the
importance of preventing bone loss in ageing. Future
work will focus on the influence of lifespan exposures
and importance of timing on changes in BMD.
The study was the first to highlight that the most
common symptom of the transition was, in fact,
“aches and joint pains” [155] rather than “hot flashes”.
Further work explored these common symptoms and
noted the prevalence of osteoarthritis in women [59],
as well as its relationship to menopause [156] and
risk factors [157]. This research also contributed to
important study design considerations for epidemio-
logical research into arthritis [158].
Lifestyle, vascular risk and prevention
The WHAP has reported on preventive testing with
mammography [40]. Recent reviews have noted the pau-
city of research examining cardiac risk factors specific to
women [159, 160]. The WHAP has shown that weight
gain and obesity are prevalent [161] and that weight
does influence hormone levels [53]. The earlier phase of
the WHAP reported risk factors for coronary heart
disease across the menopausal transition [162] and the
influence of hormones [163, 164]. Newer measures of
vascular risk have also been examined such as impaired
fasting glucose [165], homocysteine, CRP and hormone
therapy [166]. There have been a number of papers look-
ing at midlife physical activity, the changes over meno-
pausal transition [167] and impacts on health [168, 169].
These factors will be particularly important to examine
in terms of longer term health outcomes, now being
measured in follow-up.
Full nutrition surveys have been conducted over the
20-year study and some early work examining the rela-
tionship of diet to vascular risk [170] and consumption
of dietary phytoestrogens [171] has been published.
Alcohol use and its relationship to key variables has
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been reported for early ageing [172]. However the large
and relevant nutrition data-set is still largely untapped.
Women’s health and hormonal transition
The study made major contributions to methodological
considerations of reproductive ageing with a large body of
published research towards defining the stages [173–178]
and symptoms [179, 180] of the menopausal transition.
Our study also combined with North American cohorts in
the ReSTAGE collaboration to inform the new Stages of
Reproductive Aging Workshop + 10 (STRAW+ 10) cri-
teria for postmenopause [181].
The study has provided much information on the preva-
lence and importance of symptoms [17, 182–184] and
their influence on health-seeking behavior [185, 186]. The
cohort has informed management of incontinence [187]
and in particular vasomotor symptoms [188, 189] with
important research on the relationship of these symptoms
to the menstrual cycle [190].
Some of the most important work on defining the
hormonal changes across the menopause came from the
first decade of this study [19, 191–200]. Prior to these
results, it was believed that androgens such as testoster-
one dropped significantly during the menopausal transi-
tion. Our study showed that there was little change in
testosterone during this time period and the level of free
or non-bound testosterone actually increased with the
transition. The study also described patterns of hormone
therapy use in Australian women [201, 202]. The impact
of obstetric procedures such as tubal ligation, D&C
[203] and hysterectomy [204], including longer term
outcomes [205], was also examined.
International focus
The study has been active in international collabora-
tive research including cross-cultural comparisons
[206–213]. It has contributed to international stan-
dards for sexual function research [214, 215] and rec-
ommendations for staging reproductive ageing [181]
including defining criteria [216].
There are several position papers on the menopausal
transition [217, 218], vasomotor symptoms [219], som-
atic symptoms [220], and on hormonal change [217]. It
has also contributed influential position papers regarding
statistical techniques and study design for longitudinal
data [221] in addition to clinical management position
papers on mental health [211–213] and osteoporosis
[152]. The research program has developed and vali-
dated scales for measuring sexuality [35, 222] and phys-
ical activity in midlife women [223].
Discussion
The WHAP has evolved over the two decades from
a small research team into a broad international
network of researchers with oversight from the
Scientific Advisory Board. The importance of robust
ongoing measures across the lifespan continues to
provide crucial evidence on the timing and duration
of risk and potential therapeutic windows. This is
particularly relevant for chronic diseases. The holis-
tic approach taken by the research group in conjunc-
tion with our collaborative partnerships has seen
validated scales from various specialty areas utilized
which will now permit genuine multi-morbidity re-
search as the women enter ageing.
Strengths and limitations
The value of longitudinal research is in repeated mea-
sures, but particular challenges arise in a study of
now more than two decades. Technological advances
lead to the development of new and improved mea-
sures over time. In research strategic planning, con-
sidering the use of those cutting edge technologies, is
an important consideration for “future-proofing” the
study. Such an example is our choice to conduct 3 T
MRI scans in 2002 (then only available in Melbourne,
at the Brain Research Institute). A decade later in
2012, when 3 T scans were standard in all centres,
comparable scans could be obtained. An important
way to counteract biomarker technological advances
is biobank storage, which has been a crucial compo-
nent of our study, allowing novel biomarkers to be
tested on stored samples. Some changes are difficult
to anticipate, but our consenting for data-linkage in
the early years of the study when only basic govern-
ment registry data was available now facilitates na-
tional and international collaborations and linkages to
widely utilized electronic data sources.
Another limitation of such longitudinal research is
that validated scales from population-based research
have generally not been validated in older adults (over
70 years). Further methodological challenges occur
with the development of particular rating scales, such
as the CES-D (validated to age 65) which has an alter-
nate geriatric form, the GDS-15 (validated in older
ages). This circumstance requires consideration of the
value of consistent follow-up measures with the same
scale versus the evidence that inclusion of somatic
symptoms in older age groups leads to over-reporting
of depressed mood. The narrow age range of the sam-
ple has allowed examination of factors and outcome
without a large confounding from age, but is only then
representative of a decade age span. As in any cohort
of long duration, those participants remaining in the
follow-up are also healthier and slightly more educated
[20]. Initial inclusion for the longitudinal cohort ex-
cluded those with hysterectomy which impacts the
generalizability of the findings.
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Future
The WHAP is continuing follow-up in order to provide
an essential resource of longitudinal prospective research
in women from 45 years of age through to their 90s,
notably absent in Australia. Research areas will focus on
the major causes of morbidity and mortality in post-
menopausal women which include cardiovascular dis-
ease, mental health disorders (depression and dementia),
and musculoskeletal and bone health. These have all
been linked to menopausal hormonal changes. Large
clinical trials of various forms of hormone therapy have
shown age-dependent variation in results with increasing
evidence of the timing hypothesis [224].
Chronic diseases are recognised as the largest con-
tributor to death, morbidity and disability in our ageing
society [225, 226] and globally in the western world
[227]. The aetiology of these diseases involves decades of
exposure, which therefore requires decades of longitu-
dinal follow-up to examine factors associated with
disease development. In addition, chronic diseases are
known to have large overlaps in risk factors and 80 % of
our elderly suffer from 2 or more morbidities [228].
However research is disease-centered with a recent
Lancet publication noting that this practice has led to a
lack of translation to practice given the majority of those
over 50 years of age have not one but several coexisting
conditions [229]. Our study, with measures across
several disease areas, is ideally placed to examine such
multi-morbidity outcomes. Therefore, the greatest value
to this field of research will now come from follow-up
measures as women age. The WHAP study will be
uniquely placed to examine midlife associations with
later cognitive, bone, mental and vascular health,
cerebral, bone and blood pathology, and function and
also to examine temporal aspects on the development of
disease – a key factor in chronic diseases which have a
20–30 year prodrome.
Collaboration
The WHAP encourages collaboration and in particular
cross-cultural studies and combined cohort studies that
leverage synergistic datasets. The data is available through
BioGrid Australia Limited which is a leading data sharing
organisation providing a secure infrastructure that advances
health research by linking participant-level, privacy-
protected and ethically approved, clinical, biospecimen,
genetic and imaging data among a wide network of health
collaborators [230]. The cognitive dataset is also included
in the Global Alzheimer’s Association Interactive Network
[231]. The research program has nurtured a growing cohort
of alumni from undergraduate students to higher degree
students, scientists and health professionals completing
postgraduate research training. The data-set is open for
analysis towards higher degree study [16].
Additional file
Additional file 1: Changes to the instrumentation and assay techniques
for blood biomarker analysis across two decades of the Women’s Healthy
Ageing Project. (DOCX 13 kb)
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